Delving into the Latest Updates on Groupe Fournier with Synapse

Overview

Basic Info

Introduction

Groupe Fournier is a privately-owned corporation based in France that specializes in the production of medical dressings with elastic properties.

AbstractPurpose: The present study evaluated the expression of alpha1-adrenoceptor subtypes in human corpus cavernosum.Materials and Methods: The mRNA encoding alpha1a, and alpha1b and alpha1d subtypes were assessed by RNA-directed complementary cDNA synthesis followed by Taq DNA amplification. The level of alpha1 mRNA was calculated in arbitrary optical density units and normalized with respect to the length of the respective cDNA fragments.Results: We found that alpha1a, alpha1b and alpha1d adrenoceptor subtypes are expressed in human corpus cavernosum, with a predominant expression of the alpha1a subtype.Conclusion: These results suggest that alpha1a-adrenoceptor subtype is important and that understanding the biochemical and functional characteristics of this subtype may lead to the development of specific antagonists in the treatment of impotence.

01 Jun 1997·Journal of UrologyQ1 · MEDICINE

Antiproliferative Effect of Pygeum Africanum Extract on Rat Prostatic Fibroblasts

Q1 · MEDICINE

Article

Author: Nicolas, Veronique ; Yablonsky, Francoise ; Riffaud, Jean Pierre ; Bellamy, Francoise

The effect of a Pygeum africanum extract (Tadenan) (Pa), used in the treatment of micturition disorders associated with BPH, has been examined on the proliferation of rat prostatic stromal cells stimulated by different growth factors. EGF, bFGF, and IGF-I but not KGF are mitogenic for prostatic fibroblasts in culture. Pygeum africanum inhibits both basal and stimulated growth with IC50 values of 4.5, 7.7 and 12.6 micrograms./ml. for EGF, IGF-I and bFGF, respectively, compared to 14.4 micrograms./ml. for untreated cells, the inhibition being stronger towards EGF. Pygeum africanum inhibited the proliferation induced by TPA or PDBu in a concentration-dependent manner with IC50 values of 12.4 and 8.1 micrograms./ml. respectively. The antiproliferative effects of Pa were not ascribed to cytotoxicity. These results show that Pygeum africanum is a potent inhibitor of rat prostatic fibroblast proliferation in response to direct activators of protein kinase C, the defined growth factors bFGF, EGF and IGF-I, and the complex mixture of mitogens in serum depending on the concentration used. PKC activation appears to be an important growth factor-mediated signal transduction for this agent. These data suggest that therapeutic effect of Pygeum africanum may be due at least in part to the inhibition of growth factors responsible for the prostatic overgrowth in man.

01 Apr 1996·Journal of UrologyQ1 · MEDICINE

Protective Effect of Tadenan of Bladder Function Secondary to Partial Outlet Obstruction

Q1 · MEDICINE

Article

Author: Bellamy, F. ; Habib, Mohamed ; Wein, Alan J. ; Rohrmann, Dorothea ; Riffaud, J.-P. ; Zhao, Yang ; Levin, Robert M. ; Krasnopolsky, Lev

PURPOSETadenan (DEBAT, Paris, France) is a pharmaceutical agent used in the treatment of benign prostatic hyperplasia (BPH). The specific aim of this study was to determine if pretreatment of rabbits with Tadenan reduced either the hypertrophic response of the bladder to partial outlet obstruction or the accompanying contractile dysfunction.MATERIALS AND METHODSTwenty-five male New Zealand rabbits (3 to 5 kg.) were separated into 5 groups of 5 rabbits each. Each rabbit in groups 1,2, and 3 received Tadenan orally at 1, 10 and 100 mg./kg./day for 3 weeks. Group 4 received vehicle only (peanut oil); Group 5 were controls. The bladders were evaluated (in vitro studies) after 2 weeks of obstruction.RESULTS1) Tadenan did not reduce the effect of partial outlet obstruction on bladder mass. 2) Tadenan pretreatment resulted in a significant protective effect on the contractile responses to field stimulation, bethanechol and KCl.CONCLUSIONSThese results clearly demonstrate that Tadenan pretreatment protected the bladder from the contractile dysfunctions induced by partial outlet obstruction.

100 Deals associated with Groupe Fournier

Login to view more data

100 Translational Medicine associated with Groupe Fournier

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

8

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

R-7621 ( GABA receptor )	Epilepsy More	Discontinued
Tresperimus triflutate ( HSC70 )	Graft Rejection More	Discontinued
QRS-5005	Shock, Septic More	Discontinued
Beciparcil	Thrombosis More	Discontinued
Anisperimus ( CASP10 x caspase 8 )	Graft Rejection More	Discontinued